Brown Miller Wealth Management LLC Takes Position in Eli Lilly and Company (NYSE:LLY)

Brown Miller Wealth Management LLC bought a new stake in Eli Lilly and Company (NYSE:LLY) during the first quarter, HoldingsChannel reports. The institutional investor bought 348 shares of the company’s stock, valued at approximately $288,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Knightsbridge Asset Management LLC raised its position in Eli Lilly and Company by 1.9% in the fourth quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company’s stock valued at $628,000 after purchasing an additional 15 shares during the period. Centerpoint Advisory Group acquired a new position in shares of Eli Lilly and Company during the fourth quarter worth $514,000. LS Investment Advisors LLC grew its stake in shares of Eli Lilly and Company by 1.7% during the first quarter. LS Investment Advisors LLC now owns 2,340 shares of the company’s stock worth $1,933,000 after purchasing an additional 40 shares in the last quarter. CSM Advisors LLC grew its stake in shares of Eli Lilly and Company by 30.6% during the fourth quarter. CSM Advisors LLC now owns 1,045 shares of the company’s stock worth $807,000 after purchasing an additional 245 shares in the last quarter. Finally, Proficio Capital Partners LLC lifted its position in Eli Lilly and Company by 30.2% in the fourth quarter. Proficio Capital Partners LLC now owns 6,739 shares of the company’s stock valued at $5,202,000 after acquiring an additional 1,562 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $807.62 on Tuesday. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The company has a market capitalization of $765.41 billion, a price-to-earnings ratio of 68.97, a price-to-earnings-growth ratio of 1.40 and a beta of 0.40. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The firm’s fifty day moving average price is $777.10 and its 200 day moving average price is $801.77.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). The company had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Eli Lilly and Company’s revenue was up 45.2% on a year-over-year basis. During the same period in the prior year, the business earned $2.58 earnings per share. On average, research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th were issued a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.74%. The ex-dividend date of this dividend was Friday, May 16th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 48.82%.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of research reports. UBS Group reduced their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating for the company in a research report on Friday, May 2nd. Erste Group Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a research report on Thursday, June 5th. Guggenheim reiterated a “buy” rating on shares of Eli Lilly and Company in a research report on Friday, May 23rd. Wall Street Zen upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Saturday, June 7th. Finally, HSBC downgraded shares of Eli Lilly and Company from a “buy” rating to a “reduce” rating and cut their price target for the stock from $1,150.00 to $700.00 in a research note on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eighteen have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $1,011.37.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.